VABYSMO Injection 1's

VABYSMO Injection 1's

Vabysmo targets and inhibits two pathways related to vision-threatening retinal conditions. These pathways lead to excess production of two proteins, Ang-2 and VEGF-A, which can harm your central vision. Too much VEGF-A causes leaky blood vessels, damaging the macula at the back of your eye. Excess Ang-2 makes blood vessels unstable, leading to leakage, inflammation, and new vessel growth. Vabysmo helps prevent the growth of these unstable vessels, reducing the risk of eye diseases like nAMD, DME, and macular edema after retinal vein occlusion.

Do not receive Vabysmo if you:

• have an infection in or around your eye
• your eye is red, inflamed, or painful
• are allergic to Vabysmo or any of the ingredients in Vabysmo.
• increasing eye pain.
• vision loss.
• sensitivity to light

Before receiving Vabysmo:

• have an eye infection
• have red eyes
• are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

Pregnancy and breastfeeding:

There is a potential risk to the unborn baby from Vabysmo. Your healthcare provider may conduct a pregnancy test before starting treatment if there is a chance you could be pregnant.

For females and males of reproductive potential - patients should use birth control before their first injection, during their treatment with Vabysmo, and for 3 months after their last dose of Vabysmo. Vabysmo should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus.

Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if Vabysmo passes into breast milk. Talk to your doctor about the best way to feed your baby if you receive Vabysmo.